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Abstract
This paper reports the most cost-effective policy options to support and improve breast cancer control in Costa Rica and
Mexico. Total costs and effects of breast cancer interventions were estimated using the health care perspective and WHO-
CHOICE methodology. Effects were measured in disability-adjusted life years (DALYs) averted. Costs were assessed in 2009
United States Dollars (US$). To the extent available, analyses were based on locally obtained data. In Costa Rica, the current
strategy of treating breast cancer in stages I to IV at a 80% coverage level seems to be the most cost-effective with an
incremental cost-effectiveness ratio (ICER) of US$4,739 per DALY averted. At a coverage level of 95%, biennial clinical breast
examination (CBE) screening could improve Costa Rica’s population health twofold, and can still be considered very cost-
effective (ICER US$5,964/DALY). For Mexico, our results indicate that at 95% coverage a mass-media awareness raising
program (MAR) could be the most cost-effective (ICER US$5,021/DALY). If more resources are available in Mexico, biennial
mammography screening for women 50–70 yrs (ICER US$12,718/DALY), adding trastuzumab (ICER US$13,994/DALY) or
screening women 40–70 yrs biennially plus trastuzumab (ICER US$17,115/DALY) are less cost-effective options. We
recommend both Costa Rica and Mexico to engage in MAR, CBE or mammography screening programs, depending on their
budget. The results of this study should be interpreted with caution however, as the evidence on the intervention
effectiveness is uncertain. Also, these programs require several organizational, budgetary and human resources, and the
accessibility of breast cancer diagnostic, referral, treatment and palliative care facilities should be improved simultaneously.
A gradual implementation of early detection programs should give the respective Ministries of Health the time to negotiate
the required budget, train the required human resources and understand possible socioeconomic barriers.
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Introduction
Due to population ageing and changing lifestyles in low-and-
middle countries (LMICs), breast cancer incidence rates are
increasing [1,2]. Given the organizational and financial constraints
faced by the health systems in LMICs the majority of breast
cancers are diagnosed at late stages [3]. Accordingly, the majority
of breast cancer deaths occur in LMICs [4,5]. The World Health
Organization (WHO) therefore states that early detection and
implementation of cost-effective interventions should be a priority
in LMICs [6]. In an attempt to support LMICs with breast cancer
control, the Susan G. Komen for the cure foundation provided a
grant to investigate the cost-effectiveness of several breast cancer
control interventions in 7 LMICs (Brazil, Colombia, Costa-Rica,
Ghana, India, Mexico and Peru) to a consortium of the WHO,
Erasmus University Rotterdam (EUR) and Radboud University
Nijmegen Medical Center (RUNMC). Cost-effectiveness analyses
may support governments in deciding how to spend scarce
resources in health care most efficiently.
In each country, during four phases, the consortium works
closely with local authorities and experts in the fields of breast
cancer, health economics, epidemiology and public policy. First, a
three-day technical workshop is held, where the consortium
explains a general cost-effectiveness model based on WHO-
CHOICE methodology (described elsewhere [7,8]) which is to be
tailored to the country specific situation. In the second phase,
lasting approximately six months, local authorities identify and
assemble the (local) data required for the cost-effectiveness model.
Subsequent in phase three, the cost-effectiveness analyses are
carried out. Thereafter, a second workshop is organized. Here the
results of the analyses are discussed among representatives of all
local institutions involved in breast cancer care and made available
for actual policy making by the local health authorities, i.e. the
fourth phase. This paper identifies the most cost-effective
interventions for breast cancer control in both Costa Rica and
Mexico from a health care perspective.
After presenting an overview of the situation regarding breast
cancer in both Costa Rica and Mexico, we discuss the methods,
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data and interventions considered in this study and discuss the
results.
Breast cancer in Costa Rica and Mexico
Cancer incidence and mortality rates are rising across Central
America [9,10]. In Costa Rica and Mexico breast cancer ranks
among the top-five causes of death for women over 25 years old
[11]. Between 1995 and 2003, breast cancer incidence increased
by 32.3% to a rate of 40.07 per 100,000 women in Costa Rica
[12]. In Mexico, breast cancer incidence increased as well and in
both countries breast cancer mortality rates have increased since
the 1980s [9,13,14]. In Costa Rica 13.14 breast cancer deaths per
100,000 women in 2006, the highest number among malignant
neoplasms, are observed. Mortality rates per 100,000 women
range from 28.19 in province ‘Dota’ to 1.23 Gua´cimo, while in
provinces ‘Los Chiles, ‘La Cruz’, and ‘Garabito’ no breast cancer
related deaths were registered [12]. In Mexico mortality rates
doubled over the last 20 years. The average mortality rate per
100,000 women in Mexico stands at 9.9 with regional differences
from 13.2 and 11.8 respectively in the Federal District and the
north to 9.7 and 7.0 respectively in the center and the south [15].
This increase caused breast cancer to overtake cervical cancer as
the most deadly cancer among females in 2006 [14,15].Where in
1979 1,144 females died from the disease, in 2006 4,497 deaths
were registered [15].
Although in Costa Rica and Mexico official recommendations
for both breast self-examination (BSE) and mammography
screening have existed for over a decade, their coverage levels
remain very low and the large majority of breast cancer patients
present at the hospital with advanced disease [16–18].
In light of the above, Non-Governmental Organizations
(NGOs) and the general public put pressure on governments in
Costa Rica and Mexico to improve treatment and early diagnosis
through screening [19,20]. Hence, both countries face choices on
efficient allocation of scarce resources for breast cancer screening.
Materials and Methods
Methods
General approach. We used the WHO-CHOICE method-
ology, described in detail elsewhere [7,8], as a basis of our analysis.
This approach compares all possible interventions in a specific
disease area to a situation where no interventions are implement-
ed. The latter, a counterfactual ‘null scenario’, acts as a reference
to compare the costs and effects of existing and new interventions.
An intervention in isolation, or a combination of different
interventions, is then implemented for 10 years in a modeled
population. However, to include effects that occur after these 10
years, this modeled-population is tracked for 100 years. This
approach enables us to make comparisons of the costs and health
effects across a wide range of competing interventions, identify
differences in relative cost-effectiveness and identify the most
efficient mix of interventions to improve population health.
Breast Cancer Model. Costs and health effects are calculat-
ed using a state transition population model developed and
explained in detail by Groot et al. [7]. Its structure is presented in
Figure 1 [7]. The model simulates the development of a national
population and accounts for births, background mortality and
breast cancer epidemiology of a country. It includes a healthy
state, a deceased state, and stage I to IV breast cancer states
following the classification of the American Joint Committee on
Cancer (AJCC) [21]. The effectiveness of each intervention is
expressed in changes in disability weights (DWs i.e. health state
valuations (HSVs)), case fatality rates (CFs, i.e. improved survival
for treatment scenarios), or in more positive stage distributions (in
awareness raising and screening interventions). Since the inter-
ventions affect mortality (i.e., CFs) and morbidity (DWs),
intervention effectiveness is expressed in disability adjusted life
years (DALYs) averted. The difference in the total number of
healthy years lived by the population between each scenario and
the null-scenario gives the population health gains in DALYs
averted.Zelle et al. [22] improved the published model [7] by
correcting HSVs for relapse, assuming that patients could only
relapse to stage IV at a constant rate [23].
Interventions. An important element of the overall project is
to select a set of appropriate interventions for breast cancer control
in LMICs. Therefore, a study group at WHO-CHOICE defined a
mix of 11 common and preferable practices in 2009 [22].
Participating countries can combine and adapt these practices to
appropriately inform their specific policy questions. For Costa
Rica and Mexico focus was placed on the cost-effectiveness of
screening & treatment combinations. The most urgent policy
questions in both countries concerned the age groups that should
be targeted for screening and whether treating Her2/NEU+
patients with Trastuzumab was cost-effective. Therefore, the basic
awareness raising intervention was excluded and different
intervention scenarios, including treatment with Trastuzumab,
were added. Combining the 11 common practices with or without
Trastuzumab led to a total of 19 scenarios. Input from local policy
makers led us to model the current situations of breast cancer
control in Costa Rica and Mexico at 80% and 70% geographic
coverage levels (i.e. reaching 80%/70% of those people who need
services) respectively. In line with WHO-CHOICE methodology
all other interventions were evaluated at a geographic coverage
level of 95% [8]. An overview of the interventions is listed in
table 1.
Data
Effectiveness. A key factor is the stage distribution of
patients presenting at the hospital, given the breast cancer stage
determines the survival and disability of the breast cancer patients
and the effectiveness of each intervention [21].
In Costa Rica we obtained the current stage distribution from
Ortiz [24], who studied breast cancer survival in Costa Rica
between 2000 and 2003. Demographic data and incidence rates
were obtained from the Statistical office of the Costa Rican
Ministry of Health (MoH). For the prevalence we used the 2004
Global Burden of Disease estimates [25].
For Mexico, we used the current stage distribution from Knaul
et al. [17], who studied 1904 patients that were all treated within
the Mexican Social Security Institute (IMSS, its abbreviation in
Spanish). Demographic data were obtained from the Mexican
National Population Council [29]. For Mexico we obtained
incidence rates based on GLOBOCAN 2008 adjusted by group of
age considering the distribution from the Mexican Histopathology
Registry 2006 [30,31]. For the prevalence in Mexico, as in Costa
Rica, we used 2004 Global Burden of Disease estimates [25].
The case fatality rates for the treatment scenarios were based on
Groot et al. (stage III & IV) and Zelle et al. (stage I & II), who
corrected those from Groot et al. for the use of chemotherapy in
stage I and II [7,22]. We take these CF’s to represent technical
efficiency, representing the maximum amount of DALYs that can
be averted based on successful implementation of breast cancer
diagnosis, treatment and follow-up. Disability weights were
derived from the Global Burden of Disease estimates for long
term sequela [25] using quality of life literature [26,27]. For stage I
we took the disability estimate of 0.086 [28] and for stage IV we
CEA in Breast Cancer Care: Costa Rica and Mexico
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combined the terminal estimate of 0.75 [28] with estimates from
quality of life literature [26].
Since screening and awareness interventions as defined in
international literature, alter the stage distribution, their effects on
the stage distribution at presentation were estimated using the
same methods applied by Zelle et al. [22]. Zelle et al. [22] use
international study results to estimate the health effects of various
screening options and account for the sensitivity of the screening
Figure 1. Graphical representation of the model showing the relationships between the different health states through the
incidence rates of breast cancer (Ix1–Ix4), the different stage specific case fatality rates (Fx1–4), and the background mortality (M)
[7]. Stage specific relapse rates to stage IV were used to correct health state valuations only (Rx1–Rx3).
doi:10.1371/journal.pone.0095836.g001
Table 1. Definition and classification of individual interventions (coverage) (based on [22]).
Treatment of individual stages Down-staging interventionsb Palliative cared
Stage I treatment: lumpectomy withaxillary dissection
and radiotherapy. Eligible patients receive tamoxifena
or chemotherapye [7,23,49].
Basic Awareness Raising (BAR): community nurses training
program+opportunistic outreach activities by community
nurses to raise breast cancer awareness and educate on
breast self-examination techniques (BSE)+enhanced media
activities [50].c
Basic Palliative Care (BPC): palliative care
volunteers training program+home-based
visits by volunteers every fortnight+pain
treatment through morphine, laxatives and
palliative radiotherapy (8 Gy in 1 fraction) for
eligible patients [49–51]
Stage II treatment: lumpectomy with axillary dissection
and radiotherapy. Eligible patients receive tamoxifena
or Chemotherapye [7,23,49].
Mass-media awareness raising (MAR): BAR+mass media
campaign [50].
Extended Palliative Care (EPC): BPC apart from
community nurses instead of palliative care
volunteers, pain treatment strengthened with
antidepressants, anti-emetics and zelodronic
acid [50–54].
Stage III treatment: modifiedmastectomy followed by
adjuvantchemotherapye and radiotherapyf.Eligible
patients receive tamoxifena [7,49].
Biennial clinical breast examination (CBE) screening in
asymptomatically women aged 40–69 years: community
nurses training program+active outreach screening by
community nurses+limited media activities [50,55].
Stage IV treatment: adjuvant Chemotherapye and
radiotherapy (10 Gy)+end of life hospitalization.
Eligible patients receive total mastectomy and/or
tamoxifena [49,56].
Biennial mammography screening in asymptomatic
women aged 50–69 years+limited media activities [7].
Treatment of stage I–IV as listed above plus the
addition of Trastuzumabg for Her2/NEU+ patients.
Biennial mammography screening in asymptomatic
women aged 40–69 years+limited media activities [7].c
aEndocrine therapy consists of 20 mg tamoxifen per day for 5 years.
bDown-staging interventions cause a shift in stage distribution and are only modeled in combination with treatment of all stages (I–IV).
cBAR was excluded as a standalone intervention in Costa Rica and Mexico.
dPalliative care interventions are only applied to stage IV patients, and substitutes stage IV treatment.
eThe (neo)adjuvant chemotherapy combination regimen consists of 7 cycles of Epirubicin, Fluorouracil and cyclophosphamide (FEC regimen) Given on an outpatient
basis.
fRadiotherapy includes a standard dose of 50 Gy given in 25 fractions of 2 Gy on an outpatient basis.
gTrastuzumab is given for 8 months.
doi:10.1371/journal.pone.0095836.t001
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method, attendance rates (80% in both countries), incidence rates
and demography in target groups. For each intervention, table 2
gives an overview of the estimates used in every stage.
Costs. In line with the WHO-CHOICE approach we
distinguished patient, program and training costs, which were
calculated by multiplying quantities of applied procedures by their
corresponding unit costs. Patient costs were dependent on patient
consumption (utilization) of explicit resources (procedures) for
diagnosis, treatment, follow-up, early detection and screening.
Although Costa Rica has developed several guidelines for
treating breast cancer over the years [18,32], local specialists
informed us that treatments differ somewhat across hospitals.
Therefore, together with these specialists, we revised the entire set
of resource items to reflect the (average) current breast cancer
treatment practices in Costa Rica.
In Mexico the health care system has three main public
institutions providing health care to different groups. Whereas the
Instituto Mexicano del Seguro Social (IMSS) covers salaried
workers in the private sector, the Instituto de Seguridad y Servicios
Sociales de los Trabajadores del Estado (ISSSTE) provides benefits
for government workers. Finally, Seguro Popular concerns
voluntary public insurance for the non-salaried workers or
unemployed. Specialists in Mexico informed us treatment and
reimbursement between these institutions may differ due to, for
example, differences in salaries and drug prices. Hence we used
resource utilization estimates of IMSS, which provides social
insurance to approximately 40% of Mexico’s population [33].
Whenever possible we used locally obtained costing data. When
not available we applied the original WHO-CHOICE estimates
for either country. These estimates are based on econometric
analysis of a detailed WHO-CHOICE database from South Africa
including a set of standard salaries, drugs, outpatient visits,
materials and supplies, capacity utilization and transportation
multipliers [34]. In Costa Rica, the CCSS provided readily
available unit costs of most breast cancer procedures. For Mexico,
contrary to Salomon et al. [35], who used the WHO-CHOICE
original estimates on costs, in this study we used a detailed micro-
costing exercise performed by IMSS [36].
Costs of the procedures used for Costa Rica and Mexico are
listed in table 3.We also integrated evaluation costs of women
presenting without breast cancer, included the costs of diagnosing
all other stages (only for stages I–IV separately) and, regarding
screening interventions, included costs for evaluating false
positives.
For the program-level costs, which capture management,
administrative, media and law-enforcement costs, and costs for
training of healthcare personnel we used local salaries and WHO-
CHOICE allocation rules for Costa Rica. For Mexico we used the
standard WHO-CHOICE program cost estimates and allocation
rules. Media and operating costs (i.e. prices for broadcasting,
flyers, and posters) were provided by the CCSS in Costa Rica and
the MoH in Mexico.
Training costs were primarily based on training the required
health care workers for each intervention. We maintained the
allocation assumptions listed in the WHO-CHOICE model as set
by Zelle et al. [22] and used local salaries and WHO standard
salaries for Costa Rica and Mexico respectively. In both countries
all costs were estimated in 2009 local currency units (i.e. Costa
Rican colones (CRC) and Mexican pesos (MXN)) and converted
to U.S. dollars (US$) using the 2009 exchange rate
(1.00US$= 560.45CRC and 1.00US$= 13.06MXN$) [34,35].
Both health effects (DALYs) and costs (US$) were discounted at
a rate of 3% annually, which is recommended by WHO-
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CHOICE [8]. Working from a health care perspective we did not
take into account travel and opportunity costs.
Cost-effectiveness analysis. The average cost-effectiveness
ratio (ACER) of each intervention is calculated by dividing the
average costs of the intervention by average number of DALYs
averted. These ACERs provide information on the set of
interventions a region should finance to maximize health gains.
The incremental cost-effectiveness ratios (ICERs) are calculated in
relation to the last intervention purchased in each country, by
dividing the incremental costs by the incremental health effects.
These ICERs are used to establish an expansion path which shows
the order in which the various interventions should be introduced
if cost-effectiveness is the only consideration [39]. Only interven-
tions with the lowest cost for additional effects are considered on
this expansion path. WHO-CHOICE defines interventions that
have a cost-effectiveness ratio of less than one times the gross
Figure 2. Cost-effectiveness of breast cancer interventions and expansion path according to Incremental Cost-Effectiveness Ratios
for Costa Rica. Dotted lines represent cost-effectiveness threshold of 1 and 3 times 2009 GDP/capita, i.e. 6,629 US$/DALY and 19,888 US$/DALY
[37,38].
doi:10.1371/journal.pone.0095836.g002
Figure 3. Cost-effectiveness of breast cancer interventions and expansion path according to Incremental Cost-Effectiveness Ratios
for Mexico. Dotted lines represent cost-effectiveness threshold of 1 and 3 times 2009 GDP/capita, i.e. 8,416 US$/DALY and 25,249 US$/DALY [37,38].
doi:10.1371/journal.pone.0095836.g003
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domestic product (GDP) per capita as very cost-effective, and those
with a ratio that falls between one and three times the GDP per
capita as cost-effective [40]. In Costa Rica, this means that
interventions that cost less than US$6,629 per DALY averted can
be considered very cost-effective, and interventions that cost
between US$6,629 and US$19,888 per DALY averted can be
considered cost-effective. For Mexico these thresholds are
US$8,416 and US$25,249 per DALY averted, respectively.
Sensitivity analysis. In line with Zelle et al. we performed a
deterministic sensitivity analysis for both Costa Rica and Mexico
to assess the impact of key parameters on our cost-effectiveness
estimates [22]. In both countries we increased the DW’s with 10%.
Whereas costs of outpatient visits were increased by 25%, we
raised the costs of mammography with 200%. In estimating the
impact of various screening interventions we decreased the
sensitivity of CBE and mammography by 25% and assumed
attendance rates of screening of 60%. When available we also used
alternative stage distributions for the current situation and
different CFs. The unit costs for surgical procedures Costa Rica
were much lower than those of Mexico. To test the impact of this
we substituted these costs with the Mexican values.
Results
Tables 4 and 5 show the results for respectively Costa Rica and
Mexico. Both costs, effects and cost-effectiveness are presented. In
Figures 2 and 3 these results are presented graphically and the
expansion paths are shown as black lines.
Costa Rica
Table 4 shows the annual number of DALYs averted in treating
the individual stages I–IV to vary between 193 (stage III) and 573
(stage II). Jointly these interventions in each stage can avert almost
1,400 DALYs per year. Adding palliative care only averts a small
number of DALYs. The costs of treating the individual stages
range between approximately US$4 million and US$5 million per
year. Adding basic and extensive palliative care programs to stage
IV treatment adds approximately US$0.1 and US$1 million to the
yearly costs of stage IV treatment. At the 80% coverage level the
current country situation in Costa Rica is highly cost-effective with
an ICER below the country’s GDP per capita, i.e. US$4,739/
DALY. In expanding Costa Rica’s breast cancer services, our
analysis shows that treatment of all stages plus a CBE screening
program targeting women between 40 and 70 years of age (I–IV+
CBE (40–70)) is the next best option. At a total yearly cost of
almost US$13 million, CBE averts 2,381 DALYs per year. This
can be considered a very cost-effective intervention as the ICER of
this intervention is below one time Costa Rica’s GDP per DALY.
From figure 2 it follows that although the ACER of
implementing mammography screening for women between 50–
70 years is still below Costa Rica’s GDP per capita per DALY, the
ICER (as compared to CBE screening) is not lower than this
threshold (i.e. the slope of the expansion path is steeper than
US$6,629/DALY). While still considered a cost-effective inter-
vention, mammography screening in age group 50–69 averts
2,619 DALYs per year at a yearly cost of US$16 million.
Increasing the age group for mammography screening to women
between 40–70 years shows a similar trend, i.e. averting 3,015
DALYs at an annual cost of US$21 million can be considered cost-
effective. Adding Trastuzumab to this intervention, while resulting
in the highest number of DALYs averted per year, i.e. 3,274
DALYs at a total yearly cost of US$29 million, is not considered
cost-effective as its ICER is above the three times GDP per DALY
threshold.
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The combinations of various interventions are all close to the
expansion path meaning they avert DALYs at a slightly less
favorable ICER but could nevertheless be meaningful to
implement. For example, expanding the current program’s
coverage to reach 95% or implementing a Mass-media Awareness
Raising program (MAR), could be interesting options if the
available budget is not sufficient to implement a screening strategy.
Mexico
Table 5 shows that the annual number of DALYs averted in the
individual stages I–IV varies between 1,503 (stage IV) and 10,629
(stage II). Jointly these interventions in each stage avert
approximately 26,000 DALYs per year. The addition of palliative
care does not gain much health.
With an ACER of US$5,715 the current situation with 70%
coverage is very cost-effective. The analysis shows it is better to
increase the coverage level of the current intervention to 95%
instead of adding Trastuzumab. In our analysis, implementing a
program of Mass-media awareness raising (MAR) buys health
most efficiently. Our results show that MAR averts 32,908 DALYs
per year at a yearly cost of US$165 million, which leads to an
ACER of US$5,021 per DALY averted. When a higher budget
would be available, implementing mammography screening for
women aged 50–70 would be the first next step. This intervention
averts 44,192 DALYs per year at an estimated yearly cost of
US$310 million. Even more resources would allow to subsequently
add Trastuzumab and increase the age group to 40–70. These
interventions fill out the expansion path and avert 47,616 and
50,714 DALYs per year at an estimated yearly cost of US$358 and
US$471 million respectively. It should be noted that a CBE
screening program, with an expected health gain of 39,769
DALYs averted at a cost of US$260 million, could be an
interesting ‘in-between’ option.
Sensitivity analysis
Sensitivity analysis showed our results to be particularly sensitive
to different assumptions on stage distribution at presentation and
case fatality rates (tables 6 and 7). The Costa Rican CFs we
obtained from Ortiz [24] differed strongly from those we deem to
reflect technical efficiency [7,22]. Using these CFs causes the
ACERs to vary between minus 82.7% for stage I and plus 65.5%
for stage II. With regards to the current stage distribution, for
Costa Rica we used the distribution from Groot et al. [7]. With
this less favorable stage distribution, the current country situation
was not part of the expansion path anymore. Rather, the CBE
screening program now became the most cost-effective.
For Mexico we ran the model with three different current stage
distributions obtained from different studies [7,41,42]. These
different stage distributions caused the ACERs to increase between
0–15%. When using the higher CFs from Salomon et al. [35] for
the intervention scenarios, the ACERs increased to a larger extent
(34.7% for the current country situation).
For both countries, changes in the other parameters also led to
different outcomes although their impact was smaller. For
example, in Costa Rica the WHO default unit costs for a
mastectomy or a lumpectomy were relatively low. Unable to
obtain these unit costs from Costa Rica, using the higher Mexican
unit costs showed their impact on the ACERs to be marginal.
Discussion
Our results indicate that in both Costa Rica and Mexico
treating stage IV disease only, or treating stage IV and providing
basic or extended palliative care is not cost-effective. In general,
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interventions ensuring more patients to present at the hospital in
earlier stages seem the most cost-effective.
These results are in line with other studies which find
mammography screening for women aged 50–70 to be cost-
effective in sub-Saharan Africa and South East Asia [7,43].
Although Ginsberg et al. did not study the cost-effectiveness of
clinical breast examination or other awareness raising programs,
they acknowledge less expensive means of early detection in
limited resource settings could be cost-effective in LMICs [43].
When modeling the expected outcomes of such strategies - though
based on limited evidence - Zelle et al. find that CBE screening or
mass media awareness raising interventions seem indeed cost-
effective in Ghana [22].
Although mammography interventions can be considered cost-
effective, their total annual costs (budget impact) are high and may
therefore not be appropriate for wide scale implementation.
If the necessary resources are not available both countries could
choose to lower coverage levels or implement interventions with
comparable ACERs (buying health just as efficiently) but with
lower budget impact. For Costa Rica, our analysis shows the most
cost-effective option for expanding the current breast cancer
services would be a CBE screening program combined with
treatment of all stages. The yearly costs of this program are about
US$12 million. In 2009, the per capita health expenditure in Costa
Rica was US$660 (10.3% of total GDP) [37]. With a population of
approximately 4.5 million, implementing a CBE screening
program would add US$2.82 to this amount (0.43% increase).
Although this increase may seem feasible, the implementation and
effectiveness of this program is highly dependent on the availability
of human resources and the capacity of the healthcare system to
refer and treat all new-found cases [44–46]. Also, if the
implementation of a CBE screening program would be unfeasible,
MAR could be an interesting option as it is slightly less cost-
effective but has a smaller yearly budget impact (US$10 million).
Yet, the very limited evidence on MAR’s effectiveness requires our
estimates to be interpreted with caution. Implementing a screening
program for which the evidence base is stronger (e.g. mammog-
raphy for women between 50–70 years of age) could be
recommended if the yearly costs of US$16 million are affordable.
Mammography screening in age group 40–70 costs much more
(about US$21 million) and is therefore less economically attractive.
The Mexican MoH already decided to start increasing the use
of the available infrastructure and mammography equipment for
the population most at risk (women 50 to 70 years old and women
with more than two risk factors). The gradual expansion will give
enough time to train the required human resources. From our
analysis the yearly costs of a mammography screening program for
women 50–70 years of age at 95% coverage eventually would be
US$310 million per year, a threefold increase over the current
scenario. Next, once a reasonable increase on coverage would be
reached the Mexican MoH plans to increase the coverage rate to
women between 40–49 years of age [47]. According to our
estimates the yearly costs of implementing such a program would
be US$422 million. With approximately 110 million inhabitants
and a per capita health expenditure of US$525 in 2009 (6.43% of
total GDP) [37], implementing these programs would add
US$2.82 (0.54% increase) and US$3.84 (0.72% increase) respec-
tively to per capita health expenditure.
However, our analysis shows perhaps that strengthening actual
MAR or CBE screening programs to be a more attractive first step
in improving breast cancer services from an economic perspective.
With yearly costs of US$165 and US$260 million if started from
zero, the strengthening of existing programs is more affordable
and more politically feasible as it would represent modest increases
to existing budgets.
One of the principal questions we received from policy makers
in both Costa Rica and Mexico concerned the addition of
Trastuzumab to the treatment regimens. In Costa Rica we
assumed 30% of the breast cancer patients have overexpression of
the HER2/neu+ gene and are eligible for Trastuzumab [48]. As a
result of adding Trastuzumab, in Costa Rica between 230–270
extra DALYs/year are averted at an additional cost of approx-
imately US$7 million per year. For Mexico we obtained the actual
proportion of patients receiving Trastuzumab in IMSS. Here the
health gains comprise between 2,800 and 3,400 extra DALYs/
year averted and the additional costs fall between US$45–51
million. It is worth noting that in Mexico Trastuzumab is already
provided as part of the treatment for all eligible women in stages I
to IV. Our analysis shows the addition of this bio-pharmaceutical
to increase the cost of treatment of stages I to IV by more than
48%, generating the need of developing public policies focused on
negotiating price reductions that can contribute to the mid- and
long-term financial sustainability. The use of tools as the ones
presented in this paper can provide technical evidence on the
benchmark price that the Mexican health system could use in
negotiations considering the threshold of one times the GDP per
capita.
The limitations regarding the model are essentially the same as
those reported in previous studies [7,22]. First, as evidence on the
effectiveness of awareness raising, CBE and mammography
screening in Costa Rica and Mexico were absent, we relied on
the same model approach as used by Zelle et al. [22]. Second,
when calculating unit costs for Mexico we did not account for the
mark up of transportation costs (as generally recommended by
WHO-CHOICE) and did not include the costs of facilities.
Including these costs would have probably resulted in slightly
higher unit costs. Third, in adopting a health care perspective we
did not take into account travel and opportunity costs. Including
these costs would probably have increased costs generally. Fourth,
we did not carry out a probabilistic sensitivity analysis. Carrying
out such analysis would have shown worse ACERs when
parameters are jointly changed in the negative direction (i.e.
higher CFs and costs/worse stage distribution). Nonetheless, our
deterministic sensitivity analysis shows the direction in which
ACERs would change is clear and our general conclusions remain
the same although the ranges of several ACERs are overlapping.
The limitations fit within the overall goal of WHO-CHOICE
which is to provide general indications of cost-effectiveness, i.e. not
precise estimates of specific interventions.
In summary, for improving their current breast cancer control
programs, our analysis suggests that both Costa Rica and Mexico
would benefit from implementing strategies that advance early
detection. For these countries, a mass-media awareness raising
program and/or a CBE screening program coupled with
treatment of all stages and careful monitoring and evaluation
could be feasible options. If these strategies are implemented, the
provision of breast cancer diagnostic, referral, treatment and,
when possible, basic palliative care services is essential and should
be facilitated simultaneously.
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